correlation O
somatic O
observed O
we O
. O
mutation O
and O
the O
Furthermore O
, O
proliferation O
rate O
capacity O
between O
no O
tissue O
 
difference O
59 O
the O
relative O
DMAHP O
inter O
of O
tissue O
three O
genes O
repeat O
somatic O
The O
( O
) O
tissues O
not O
DMPK O
rates O
also O
levels O
the O
in O
mutation O
to O
were O
surrounding O
and O
correlated O
, O
. O
the O
. O
- O
transcriptional O
in O
different O
 
of O
retinoblastoma B
mutation O
the O
in O
pedigree O
patients O
mild O
a O
missense O
. O
expression O
showing O
only O
tumor B
phenotype O
Novel O
from O
a O
 
individuals O
strand O
retinoblastoma B
27 O
a O
We O
expression O
the O
of O
of O
phenotype O
polymorphism O
conformation O
the O
mild O
used O
single O
study O
exons O
family O
in O
to O
the O
from O
have O
RB1 O
. O
gene O
analysis O
showing O
 
the O
mutation O
carriers O
unaffected O
family O
were O
unilateral B
pedigree O
individuals O
developed O
of O
analysis O
a O
, O
. O
tumors I
, O
In O
identified O
and O
also O
this O
result O
within O
linkage O
as O
affected O
 
a O
position O
which O
exon O
in O
21 O
. O
cys O
> O
single O
using O
arg O
was O
converting O
- O
in O
missense O
resulted O
band O
- O
mutation O
SSCP O
the O
shift O
exon O
28 O
nucleotide O
identified O
a O
A O
at O
in O
 
an O
site O
mutation O
NdeI O
the O
restriction O
Destroyed O
. O
enzyme O
 
result O
the O
of O
predisposing O
with O
- O
patients O
demonstrated O
the O
Analysis O
members O
family O
missense O
or O
tumors B
. O
mutation O
all O
had O
been O
that O
mutation O
of O
to O
linkage O
, O
as O
who O
analysis O
segregated O
predicted O
with O
a O
carry O
co O
 
. O
distinctive O
genetic O
to O
modify O
another O
These O
of O
where O
the O
phenotypes O
only O
point O
with O
in O
observations O
. O
RB1 O
questions O
the O
and O
important O
mutations O
families O
function O
the O
counseling O
these O
of O
region O
gene O
gene O
raise O
for O
 
of O
translocation O
15 O
and O
q11 O
) O
a O
disomy I
- I
case O
Willi I
syndrome I
) O
Consistent O
in O
2 O
( O
with O
Prader B
. O
3 O
p25 O
gamete O
; O
Maternal B
; O
familial O
complementation O
. O
( O
 
responsible O
syndrome I
Willi I
cases O
of O
for O
PWS B
an O
Prader B
30 O
for I
Is O
. O
( O
( I
- I
of O
) O
estimated O
Maternal B
15 I
) I
disomy I
uniparental I
UPD I
% O
chromosome I
 
an O
disomy I
) O
of O
( O
maternal B
adjacent O
with O
- O
with O
; O
on O
report O
( O
a O
meiotic O
15 O
p25 O
consistent O
case O
1 O
t O
. O
2 O
We O
paternal O
that O
in O
15 O
for O
nondisjunction O
simultaneous O
maternal O
. O
q11 O
is O
3 O
) O
segregation O
chromosome O
15 I
of O
most O
unusual O
PWS B
; O
 
the O
( O
) O
17 O
the O
and O
chromosome O
Patient O
B O
have O
supernumerary O
found O
year O
arm O
arm O
distal O
der O
long O
a O
with O
old O
( O
, O
. O
- O
was O
short O
with O
15 O
- O
, O
) O
15 O
chromosome O
. O
proximal O
. O
and O
, O
PWS B
J O
, O
white O
arm O
of O
47 O
paternal O
male O
the O
consisting O
chromosomes O
3p O
a O
of O
to O
 
t O
patients O
present O
balanced O
; O
the O
in O
) O
was O
state O
in O
The O
father O
and O
3 O
a O
. O
sister O
the O
15 O
( O
 
present O
pair O
Fluorescent O
that O
in O
region O
the O
and O
situ O
15s O
of O
demonstrated O
critical O
hybridization O
analysis O
normal O
on O
of O
the O
that O
resided O
. O
J O
was O
chromosome O
no O
in O
3 O
deletion O
PWS B
the O
there O
PWS B
the O
region O
on O
derivative O
 
. O
B O
 
pattern O
characteristic O
. O
maternal O
nuclear O
the O
) O
in O
ribonucleoprotein O
polypeptide O
at O
exon O
N O
only O
associated O
J O
the O
( O
chromosome O
- O
gene O
of O
Methylation O
small O
analysis O
SNRPN O
of O
showed O
alpha O
15 O
a O
 
B O
. O
 
beta3 O
the O
. O
Maternal B
GABRB3 O
locus O
subunit O
( O
was O
reaction O
- O
acid O
polymerase O
at O
receptor O
aminobutyric O
by O
chain O
repeats O
confirmed O
of O
) O
microsatellite O
analysis O
gamma O
disomy I
 
that O
derivative O
without O
with O
B O
distal O
B O
der O
. O
chromosomes O
with O
) O
reported O
Niece O
haploinsufficiency O
a O
. O
the O
( O
45 O
. O
of O
3 O
3 O
( O
the O
phenotype O
a O
15 O
for O
and O
demonstrated O
) O
consistent O
but O
p O
 
previously O
been O
been O
case O
Associated O
our O
with O
- O
but O
. O
of O
, O
Robertsonian O
segregation O
, O
PWS B
observed O
in O
non O
of O
knowledge O
disomy I
translocations O
has O
a O
has O
not O
reported O
to O
unbalanced O
Uniparental B
 
15 I
resulting O
and O
Furthermore O
in O
PWS B
as O
gamete O
, O
interpreted O
complementation O
are O
findings O
best O
true O
maternal B
our O
UPD I
 
syndrome I
- I
for O
- I
2 I
and O
a O
. O
case O
Jampel I
" O
lumping O
" O
: O
Schwartz B
type I
Stuve B
syndrome I
Wiedemann I
 
existence O
distinct O
( O
of O
Recent O
lethal O
the O
SJS B
form O
SJS B
myotonia B
dysplasia I
2 I
of O
. O
Schwartz B
skeletal B
studies O
syndrome I
we O
Jampel I
genetically O
the O
called O
which O
, O
type I
demonstrated O
, O
of O
and O
usually O
- I
a O
) O
 
. O
the O
and O
, O
with O
is O
This O
skeletal B
, O
- I
, O
early B
Wiedemann I
of O
rare O
dysplasia I
syndrome I
, O
SWS B
) O
at O
Stuve B
disorder O
contractures B
( O
condition O
reminiscent O
comprises O
campomelia B
death I
birth O
which O
another O
 
years O
type I
nosologic O
of O
with O
follow O
years O
SJS B
patients O
identity O
only O
To O
, O
possible O
at O
7 O
2 I
surviving O
literature O
and O
the O
at O
. O
the O
with O
up O
a O
obtained O
another O
two O
, O
age O
one O
for O
SWS B
these O
disorders O
we O
reviewed O
between O
- O
10 O
and O
age O
test O
 
tendency O
reported O
prenatal O
onset O
with O
, O
disorder I
and O
of O
having O
- O
to O
skeletal I
- I
death O
distinct O
campomelic B
combination O
and O
a O
feeding O
SWS B
neonatal O
in O
. O
with O
, O
) O
a O
joint I
contractures I
a O
dysplasia I
, O
respiratory O
difficulties O
neuromuscular B
congenital B
metaphyseal I
( O
hyperthermia B
Patients O
either O
severe O
or O
, O
infancy O
presented O
frequent O
as O
SJS B
 
and O
is O
a O
radiographic O
The O
so O
that O
appear O
the O
disorders O
of O
these O
entity O
clinical O
to O
be O
findings O
single O
extensive O
similarity O
. O
 
of O
- O
with O
in O
to O
SWS B
adds O
, O
progressive O
an O
) O
one O
identity O
evidence O
dysplasia I
identical O
. O
in O
one O
of O
pattern O
SJS B
beyond O
bone B
the O
surviving O
the O
( O
and O
of O
the O
with O
two O
observation O
up O
Follow O
type I
patients O
2 I
infancy O
unique O
favor O
 
the O
and O
The O
be O
. O
. O
2 I
SWS B
are O
type I
should O
methods O
SJS B
that O
testable O
same O
molecular O
hypothesis O
disorder O
by O
 
defects O
severe O
disease I
thrombosis B
von B
model O
. O
: O
of O
A O
mouse O
hemostasis O
Willebrand I
in O
and O
 
) I
causes O
Willebrand I
severe O
humans O
von B
. O
factor I
von B
vWf I
Willebrand I
in O
disease I
( I
deficiency I
 
gene O
mouse O
by O
a O
using O
Generated O
model O
this O
for O
we O
. O
disease O
targeting O
 
; O
deficient I
appeared O
and O
birth O
. O
- I
were O
vWf B
normal O
fertile O
mice O
they O
viable O
at O
 
homozygous O
mice O
plasma O
platelets O
( O
, O
were O
the O
, O
Willebrand I
von B
) O
detectable O
cells O
or O
endothelial O
in O
nor O
antigen O
. O
propolypeptide O
of O
neither O
vWf O
II O
mutant O
vWf O
 
10 O
highly O
events O
bleeding O
in O
spontaneous O
a O
bleeding O
defects O
approximately O
Mutant O
with O
mice O
% O
exhibited O
time O
prolonged O
. O
neonates O
the O
in O
and O
hemostasis O
of O
 
protection O
in O
strongly O
factor O
these O
of O
a O
reduced O
the O
of O
by O
disease O
VIII O
the O
level O
as O
, O
the O
in O
result O
mice O
lack O
provided O
vWf O
human O
was O
. O
As O
 
injury I
model O
mutant O
an O
thrombosis B
Defective O
vascular B
. O
of O
in O
vivo O
in O
evident O
mice O
was O
in O
also O
 
the O
of O
intravital O
ferric O
, O
In O
was O
model O
exteriorized O
the O
this O
accumulation O
was O
mesentery O
superfused O
chloride O
. O
by O
labeled O
observed O
with O
platelets O
and O
fluorescently O
microscopy O
 
mimic O
these O
in O
normal O
closely O
vWf O
mice O
Willebrand I
von B
models O
will O
. O
the O
and O
investigating O
in O
disease O
that O
and O
very O
useful O
human O
for O
severe O
very O
be O
Conclude O
of O
. O
disease I
role O
physiology O
we O
 
ovarian I
. O
risk O
of O
hereditary B
and O
Contraceptives O
cancer I
oral O
the O
 
Ovarian I
clinical O
Study O
Group O
. O
Cancer I
Hereditary B
 
or O
risk O
with O
a O
mutations O
BACKGROUND O
BRCA2 O
high O
of O
the O
in O
Women O
cancer I
lifetime O
. O
the O
ovarian B
BRCA1 O
have O
gene O
either O
 
not O
of I
protect O
in O
contraceptives O
, O
. O
is O
oral O
against O
cancer I
protect O
cancer I
Against O
also O
ovarian B
it O
general O
but O
whether O
forms I
ovarian I
hereditary B
known O
they O
 
of O
in O
cancer I
- O
and O
ovarian I
case O
a O
. O
as O
hereditary B
their O
control O
161 O
women O
with O
sisters O
enrolled O
METHODS O
controls O
207 O
We O
study O
 
women O
BRCA2 O
BRCA1 O
28 O
or O
) O
all O
either O
( O
179 O
women O
patients O
carried O
mutation O
) O
a O
pathogenic O
( O
. O
The O
in O
 
of O
regardless O
they O
control O
were O
Women O
not O
the O
either O
whether O
enrolled O
. O
or O
mutation O
had O
 
- O
compared O
were O
by O
control O
contraceptive O
by O
lifetime O
, O
and O
of O
adjustment O
interview O
year O
of O
and O
and O
between O
Histories O
oral O
or O
birth O
use O
for O
obtained O
written O
questionnaire O
parity O
after O
patients O
women O
were O
. O
 
adjusted O
was O
past O
ovarian B
The O
cancer I
ratio O
. O
odds O
any O
for O
RESULTS O
contraceptives O
associated O
0 O
with O
of O
oral O
use O
 
to O
percent O
5 O
. O
) O
. O
0 O
, O
. O
( O
8 O
confidence O
95 O
3 O
interval O
0 O
 
001 O
percent O
of O
. O
; O
. O
, O
a O
duration O
was O
decreased O
risk O
or O
six O
P O
for O
0 O
60 O
use O
use O
for O
reduction O
The O
< O
risk O
with O
with O
( O
more O
) O
associated O
increasing O
years O
in O
trend O
 
, O
BRCA1 O
use O
) O
odds O
( O
. O
- O
percent O
0 O
odds O
the O
2 O
mutation O
ratio O
3 O
percent O
. O
interval O
) O
both O
1 O
mutation O
protected O
0 O
interval O
the O
for O
ratio O
9 O
95 O
; O
to O
95 O
ovarian B
carriers O
against O
. O
0 O
; O
, O
. O
and O
confidence O
BRCA2 O
for O
to O
1 O
of O
oral O
. O
. O
carriers O
cancer I
0 O
Contraceptive O
confidence O
. O
of O
, O
0 O
, O
4 O
5 O
( O
 
risk O
the O
BRCA2 O
the O
pathogenic O
cancer I
women O
or O
gene O
- O
BRCA1 O
mutations O
with O
reduce O
in O
CONCLUSIONS O
ovarian B
of O
Oral O
may O
contraceptive O
in O
use O
 
adrenoleukodystrophy B
A O
report O
, O
, O
clinical O
: O
with O
codon O
deletion O
family O
a O
biochemical O
. O
291 O
genetic O
a O
and O
with O
Japanese O
, O
pathological O
 
base O
adrenoleukodystrophy B
Japanese O
in O
ALD B
291 O
family O
( O
a O
three O
gene O
with O
We O
pair O
ALD B
delGAG O
with O
) O
( O
the O
. O
report O
deletion O
) O
a O
 
within O
phenotypes O
observed O
this O
variety O
. O
family O
of O
were O
A O
 
( O
) O
and O
younger O
brother O
2 O
- O
intermediate O
having O
cerebello O
as O
classified O
patient O
) O
was O
. O
type O
and O
( O
cerebral O
childhood O
) O
proband O
forms O
had O
brain O
a O
( O
, O
his O
1 O
patient O
nephew O
While O
a O
stem O
the O
of O
patient O
type O
adult O
3 O
ALD B
rare O
 
4 O
( O
an O
adolescent O
. O
having O
form O
) O
of O
patient O
nephew O
as O
Another O
patient O
1 O
was O
classified O
 
that O
of O
AD B
as O
fluid O
CSF O
) O
patients O
The O
( O
) O
with O
1 O
tau O
patient O
as O
Alzheimers B
. O
was O
( O
disease I
high O
in O
level O
the O
cerebrospinal O
in O
 
the O
oxygen O
Magnetic O
were O
not O
) O
. O
flow O
MRI O
emission O
the I
matter O
in O
abnormalities B
in I
and O
( O
cerebral O
of O
PET O
white O
reductions O
the O
, O
resonance O
brain O
( O
image O
cerebral O
stem O
cerebellar I
his O
blood O
tomography O
hemispheres I
clearly O
and O
demonstrated O
marked O
, O
metabolism O
showed O
bilateral I
brain O
) O
positron O
but O
where O
by O
 
and O
with O
, O
cerebral I
of I
3 O
of O
fibers O
, O
matter I
of O
. O
- O
ALD B
with O
compatible O
demyelination B
the O
the O
massive O
showed O
findings O
childhood O
the O
sparing O
findings O
white I
2 O
autopsy O
U O
patients O
In O
the I
 
Oil O
acids O
was O
were O
( O
) O
and O
effectiveness O
sufficient O
Lorenzos O
, O
and O
Oleic O
patients O
obtained O
administered O
but O
not O
4 O
1 O
to O
erucic O
. O
 
phenotypic O
of O
family O
cause O
ALD B
. O
suggest O
The O
with O
findings O
is O
variations O
the O
delGAG291 O
of O
part O
Japanese O
in O
that O
this O
 
neuronal B
or O
MRI O
is O
computed O
that O
PET O
reflects O
that O
insidious B
. O
tau O
lesion I
Moreover O
the O
of O
and O
an O
limited O
) O
process O
the O
detect O
is O
study O
there O
by O
( O
analysis O
CT O
possibility O
which O
scale O
undetectable O
the O
of O
tomogram O
in O
level O
a O
although O
, O
, O
higher O
is O
the O
, O
can O
degeneration I
of O
ALD B
 
. O
early O
be O
. O
Lorenzos O
the O
stage O
in O
given O
should O
Oil O
 
C9 I
deficiency I
of O
gene O
Japanese O
4 O
cause O
C9 O
of O
. O
human O
exon O
complement B
in O
complement O
Mutation O
the O
major O
is O
nonsense O
 
of I
but O
complement B
in O
Deficiency B
ninth I
other O
the O
the I
in O
deficiency I
is O
component I
common O
countries O
human I
C9 O
of I
most O
complement I
rare O
( O
Japan O
is O
. O
) O
 
deficient I
the O
in O
had O
patients O
molecular O
studied O
meningococcal B
- I
. O
suffered O
deficiency I
who O
C9 B
from O
C9 B
We O
basis O
Japanese O
meningitis I
four O
of O
 
at O
nonsense O
Sequencing O
in O
95 O
- O
CGA O
C9 B
substitution O
and O
in O
TGA O
cDNA O
) O
four O
C9 O
exon O
individuals O
a O
- I
the O
amplified O
DNA O
4 O
revealed O
> O
. O
direct O
- O
of O
deficient I
codon O
( O
 
only O
indicated O
in O
the O
chain O
specific O
polymerase O
allele O
that O
heterozygous O
were O
of O
4 O
the O
alleles O
the O
homozygous O
- O
four O
system O
all O
mutation O
2 O
and O
the O
exclusively O
mutant O
parents O
exon O
that O
normal O
detect O
. O
to O
one O
An O
were O
and O
patient O
reaction O
for O
designed O
patients O
of O
 
might O
be O
Japanese O
most O
for O
Mutation O
codon O
common O
95 O
. O
in O
deficiency I
responsible O
. O
exon O
4 O
the O
C9 B
at O
 
damage O
BRCA1 O
oxidative O
- O
Required O
. O
of O
coupled O
repair O
DNA O
for O
transcription O
 
breast B
function O
. O
ovarian I
gene O
encodes O
cancer I
and I
finger O
unknown O
protein O
a O
susceptibility O
BRCA1 O
zinc O
of O
The O
 
protein O
DNA O
the O
changes O
with O
BRCA1 O
and O
the O
Rad51 O
Association O
agents O
the O
with O
a O
BRCA1 O
DNA O
repair O
consistent O
DNA O
role O
protein O
in O
in O
to O
of O
of O
repair O
cellular O
the O
localization O
phosphorylation O
- O
are O
after O
. O
and O
damaging O
for O
protein O
exposure O
 
it O
, O
oxidative O
of O
to O
and O
Here O
coupled O
deficient B
are O
defective O
hydrogen O
peroxide O
to O
ability O
mouse O
is O
. O
carry O
, O
hypersensitive O
damage O
embryonic O
out O
ionizing O
transcription O
and O
shown O
in O
- O
radiation O
DNA O
in I
that O
BRCA1 I
cells O
the O
stem O
are O
repair O
 
damage O
. O
results O
in O
oxidative O
participates O
- O
or O
DNA O
that O
, O
repair O
coupled O
, O
suggest O
transcription O
BRCA1 O
of O
. O
directly O
indirectly O
These O
 
in O
. O
PAX6 O
transactivation O
region O
- O
negative O
of O
mutants O
Truncation O
result O
in O
the O
mutations O
dominant O
 
proline O
homeobox O
binding O
transactivation O
serine O
two O
( O
PAX6 O
. O
domains O
and O
rich O
DNA O
a O
paired O
a O
) O
threonine O
box O
domain O
factor O
- O
with O
) O
transcription O
is O
PST O
and O
( O
- O
- O
- O
 
. O
eye O
to O
development O
Drosophila O
in O
humans O
ranging O
to O
jellyfish O
animals O
regulates O
from O
PAX6 O
 
. O
human O
, O
Peters B
various O
anomaly I
in O
gene O
foveal I
aniridia B
and O
familial B
result O
, O
mutations O
Heterozygous O
the O
keratitis I
, O
, O
autosomal B
PAX6 O
including O
dysplasia I
phenotypes O
in O
dominant I
 
allele O
of O
due O
protein O
that O
believed O
haploinsufficiency O
inactive O
mutated O
aniridia B
It O
is O
produces O
caused O
genetic O
to O
. O
an O
the O
and O
is O
PAX6 O
 
transactivation O
, O
binding O
mutations O
domains O
to O
of O
have O
mutant O
in O
proteins O
occur O
several O
in O
- O
found O
However O
patients O
DNA O
lost O
most O
C O
of O
retain O
have O
- O
in O
truncation O
resulting O
the O
half O
domain O
but O
that O
Aniridia B
PAX6 O
the O
with O
terminal O
the O
been O
. O
 
as O
mutants O
clear O
- O
such O
as O
function O
of O
predicted O
loss O
It O
. O
mutants O
not O
behave O
by O
haploinsufficiency O
is O
whether O
- O
really O
 
data O
when O
mutants O
our O
negative O
coexpressed O
, O
To O
they O
this O
assays O
wild O
transfection O
are O
with O
- O
- O
type O
PAX6 O
showed O
that O
these O
transient O
theory O
contrary O
. O
in O
dominant O
are O
 
- O
enhanced O
of O
from O
negative O
result O
DNA O
we O
ability O
Found O
dominant O
the O
. O
binding O
the O
these O
that O
effects O
mutants O
 
dissociation O
studies O
the O
type O
to O
- O
. O
Kinetic O
binding O
when O
various O
mutants O
of O
various O
higher O
- O
binding O
- O
- O
revealed O
affinity O
PAX6 O
DNA O
wild O
sites O
have O
compared O
5 O
that O
3 O
truncation O
with O
fold O
and O
 
results O
insight O
role O
new O
into O
aniridia B
a O
PAX6 O
in O
the O
. O
provide O
mutant O
causing O
These O
. O
of O
 
very B
coenzyme I
in O
cardiomyopathy I
- I
. O
Reversal O
acyl I
of O
- I
long I
dehydrogenase I
deficiency I
outcome O
neuropsychologic O
chain I
and O
- I
A I
severe O
excellent O
hypertrophic B
 
a O
VLCAD I
is O
A I
has O
Very B
acid O
that O
long I
morbidity O
high O
) I
and O
dehydrogenase I
coenzyme I
deficiency I
fatty O
oxidation O
- I
of O
( I
chain I
. O
rates O
- I
disorder O
acyl I
beta O
mortality O
reportedly O
of O
- I
 
with O
5 O
and O
was O
we O
a O
age O
of O
, O
at O
- O
of O
hepatomegaly B
5 O
year O
seen O
. O
deficiency I
, O
first O
cardiomyopathy I
hypotonia B
Describe O
severe O
outcome O
hypertrophic B
old O
who O
with O
girl O
, O
months O
the O
VLCAD B
encephalopathy B
- O
 
VLCAD B
enzyme O
inactive O
a O
biochemical O
studies O
yet O
Indicated O
caused O
deficiency I
stable O
by O
. O
 
1669 O
mutation O
of O
1668 O
) O
mutation O
a O
genetic O
ACAG O
( O
Molecular O
VLCAD O
splice O
missense O
T1372C O
and O
gene O
her O
a O
F458L O
revealed O
site O
. O
analysis O
 
triglyceride O
After O
medium O
- O
avoidance O
and O
- O
initial O
of O
carnitine O
a O
and O
supplemented O
patient O
fasting O
glucose O
low O
and O
carnitine O
intravenous O
treatment O
diet O
. O
, O
fat O
oil O
with O
on O
has O
chain O
with O
thrived O
the O
 
over O
year O
Ventricular O
. O
resolved O
, O
hypertrophy O
her O
the O
1 O
cognitively O
age O
, O
significantly O
in O
for O
superior O
and O
range O
is O
she O
 
one O
children O
of O
of O
is O
it O
because O
cardiomyopathy B
directly O
is O
in O
. O
VLCAD B
treatable O
Recognition O
. O
important O
deficiency I
causes O
the O
few O
of O
clinical O
 
low O
density O
Cloning O
. O
of O
lipoprotein O
the O
of O
member O
- O
receptor O
novel O
family O
a O
 
DNA O
was O
11q13 O
novel O
diabetes I
sequence O
chromosome O
on O
analysis O
IDDM4 O
) O
locus O
( O
gene O
encoding O
identified O
mellitus I
IDDM B
- I
insulin B
A O
. O
dependent I
by O
a O
protein O
the O
within O
transmembrane O
 
susceptibility O
Based O
candidate O
is O
gene O
. O
this O
chromosomal O
to O
its O
diabetes B
conferring O
a O
, O
position O
on O
for O
 
conserved O
are O
termed O
- O
density O
LRP5 O
1615 O
- O
family O
contains O
The O
) O
, O
receptor O
of O
related O
a O
modules O
amino O
protein O
( O
receptor O
density O
of O
low O
( O
encodes O
) O
LDL O
low O
which O
, O
. O
the O
acids O
characteristic O
protein O
lipoprotein O
lipoprotein O
5 O
that O
gene O
 
these O
, O
, O
domain O
for O
) O
EGF O
growth O
receptor O
with O
putative O
include O
( O
) O
factor O
. O
, O
repeats O
Modules O
three O
LDL O
four O
a O
peptide O
protein O
spacer O
signal O
a O
and O
export O
, O
domain O
associated O
spanning O
cytoplasmic O
- O
a O
epidermal O
single O
LDLR O
transmembrane O
domains O
repeats O
( O
 
family O
of O
category O
and O
protein O
has O
unique O
a O
therefore O
EGF O
likely O
the O
a O
LRP5 O
The O
encoded O
. O
new O
represents O
; O
of O
, O
repeats O
organization O
LDLR O
LDLR O
 
identical O
Both O
proteins O
human O
and O
% O
encoded O
conservation O
are O
. O
indicating O
LRP5 O
degree O
and O
95 O
a O
evolutionary O
the O
of O
cDNAs O
high O
mature O
have O
mouse O
. O
isolated O
, O
been O
 
a O
the O
are O
with O
with O
and O
tumors I
E1317Q O
history O
always O
family O
. O
associated O
not O
Variants O
, O
colorectal B
I1307K O
but O
APC B
 
carcinoma I
familial B
mutations O
adenomatous I
the O
that O
hundreds O
autosomal B
. O
adenomas I
results O
dominant I
from O
Classical O
- O
gene O
penetrance O
a O
disease I
) O
to O
predisposes O
FAP B
colorectal B
and I
of O
or O
thousands O
polyposis I
( O
is O
and O
high O
APC B
truncating O
that O
in O
 
of O
and O
5 O
germ O
line O
polyposis I
which O
a O
attenuated B
is O
adenomatous I
results O
FAP B
. O
APC B
the O
from O
- O
the O
gene O
of O
, O
mutations O
coli I
in O
regions O
3 O
Variant O
 
fewer O
FAP B
. O
classical O
without O
Attenuated B
coli I
colorectal B
" O
multiple O
" O
adenomatous I
adenomas I
) O
of O
polyposis I
Patients O
phenotype O
typically O
than O
the O
( O
have O
florid O
100 O
 
, O
a O
at O
phenotype O
Another O
mutations O
patients O
and O
adenomas B
or O
has O
, O
of O
their O
variation O
gene O
with O
the O
genome O
. O
from O
, O
in O
group O
elsewhere O
probably O
the O
APC B
results O
in O
loci O
multiple O
no O
locus O
 
confers O
. O
tumors I
of O
, O
of O
, O
described O
( O
an O
colorectal B
was O
variant O
in O
missense O
including O
however O
increased O
risk O
a O
Recently O
I1307K O
, O
multiple O
) O
APC B
that O
, O
Ashkenazim O
adenomas B
 
for O
1263 O
carcinoma I
. O
a O
15G O
164 O
have O
- O
- O
) O
and O
codons O
exon O
germ O
variants O
adenomas I
APC B
( O
with O
multiple O
the O
colorectal B
/ I
We O
line O
1377 O
patients O
of O
and I
studied O
gene O
analyzed O
of O
or I
set O
 
detected O
descent O
with O
Three O
the O
Ashkenazi O
each O
were O
patients O
. O
of O
, O
allele O
I1307K O
 
individuals O
the I
; O
in O
four O
variant O
germ O
a O
line O
- O
missense O
APC O
number O
of I
not O
metaplastic B
was O
controls O
unusually O
of O
. O
present O
colorectum I
polyps I
an O
had O
of O
large O
E1317Q O
had O
that O
Patients O
one O
of O
these O
 
evidence O
with O
phenotype O
risk O
there O
. O
development O
adenomas I
that O
, O
and O
and I
for O
classical O
germ O
the O
population O
Is O
without O
in O
increasing O
but O
that O
colorectal B
multiple O
, O
APC B
- O
variants O
line O
of O
of O
of O
the O
cancer I
the O
FAP B
. O
predispose O
to O
there O
the O
possibly O
florid O
carcinoma I
importance O
gene O
colorectal B
general O
exist O
 
gene O
. O
human O
congenital B
chloride I
( O
diarrhea I
CLD B
the O
) O
of O
genomic O
Structure O
 
encodes O
transporter O
is O
mutations O
( O
diarrhea I
by O
intestinal O
) O
CLD B
an O
gene O
caused O
a O
which O
anion O
. O
Congenital B
in O
chloride I
 
We O
and O
organization O
here O
the O
approximately O
. O
report O
comprises O
gene O
CLD B
genomic O
spans O
complete O
of O
the O
, O
exons O
human O
21 O
39kb O
which O
 
/ O
exon O
conform O
. O
AG O
boundaries O
intron O
the O
/ O
GT O
All O
to O
rule O
 
factor O
putative O
box O
multiple O
TATA O
putative O
predicts O
region O
Analysis O
and O
. O
promoter O
a O
shows O
binding O
an O
of O
the O
transcription O
sequence O
sites O
 
from O
and O
DNA O
structure O
- O
and O
The O
DNA O
genomic O
genomic O
patients O
from O
was O
multiple O
several O
including O
controls O
determined O
libaries O
using O
sources O
large O
CLD B
insert O
. O
Finnish O
 
of O
study O
in O
studies O
disease O
exon O
this O
patients O
. O
developed O
mutation O
facilitate O
the O
- O
primers O
will O
screening O
with O
Specific O
 
a O
_ O
gene O
as O
of O
. O
sequencing O
with O
RG364P16 O
another O
identified O
similar O
the O
genomic O
PDS B
of O
H O
of O
CLD B
gene O
homologous O
a O
recently O
clone O
Pendred B
, O
, O
revealed O
structure O
BAC O
syndrome I
. O
( O
Genomic O
gene O
the O
presence O
highly O
, O
) O
the O
3 O
 
Jews O
in O
risk O
. O
a O
APCI1307K O
based O
- O
of O
allele O
The O
study O
and O
Ashkenazi O
community O
cancer B
 
intestinal O
dominant I
and O
familial B
cancer I
colorectal B
polyps B
without O
of O
penetrant O
disorder I
, O
by O
autosomal B
classically O
are O
FAP B
. O
( O
with O
associated O
, O
in O
multiple O
) O
, O
highly O
polyposis I
the O
surgical O
( O
APC O
) O
adenomatous I
Mutations O
characterized O
a O
CRC B
development O
intervention O
 
in O
somatic O
. O
is O
gene O
suppressor O
, O
APC B
tumours B
and O
- O
occurs O
loss O
tumour O
A O
 
to O
T O
to O
mutation O
) O
type O
to O
unstable O
The O
somatic O
- O
allele O
and O
wild O
transversion O
that O
the O
I1307K O
sequence O
- O
germline O
a O
responsible O
A O
converts O
( O
is O
for O
prone O
APC O
A8 O
tract O
. O
- O
genetically O
the O
homopolymer O
 
allele O
I1307K O
found O
in O
6 O
. O
The O
was O
 
family O
personal O
with O
Jews O
or O
histories O
and O
CRC B
2 O
. O
of O
higher O
Ashkenazim O
( O
. O
) O
Of O
ref O
% O
unselected O
1 O
proportions O
Ashkenazi O
of O
 
volunteers O
we O
5 O
in O
a O
evaluate O
. O
, O
of O
role O
081 O
cancer B
To O
, O
Ashkenazi O
I1307K O
survey O
community O
the O
in O
genotyped O
 
genotyped O
colorectal B
other I
relatives O
I1307K O
were O
breast I
carriers O
, I
developing O
and I
- O
degree O
. O
non O
carriers O
- O
compared O
between O
of O
cancers I
and O
first O
Risk O
their O
and O
 
analysis O
and O
. O
both O
DNA O
FRDA B
in O
a O
carrier O
gene O
sperm O
mitotic O
in O
suggests O
Friedreich B
expansion O
the O
ataxia I
meiotic O
premutation O
 
an O
a O
is O
by O
FRDA B
Friedreich B
repeat O
gene O
of O
trinucleotide O
1 O
intron O
usually O
of O
GAA O
. O
ataxia I
the O
in O
caused O
expansion O
 
premutation O
triplet O
or O
allele O
of O
occasionally O
, O
repeats O
A O
from O
to O
100 O
fully O
less O
been O
. O
a O
expanded O
has O
found O
arise O
 
sperm O
have O
premutation O
carrier O
examined O
the O
a O
of O
DNA O
. O
We O
 
showed O
one O
one O
allele O
normal O
Mans O
. O
repeats O
of O
and O
leucocyte O
this O
DNA O
allele O
approximately O
100 O
 
expanded O
allele O
tight O
showed O
a O
size O
range O
Sperm O
repeats O
of O
approximately O
in O
320 O
centering O
trinucleotide O
his O
on O
a O
. O
an O
 
son O
has O
. O
of O
His O
540 O
and O
1040 O
repeat O
affected O
sizes O
 
meiosis O
during O
These O
first O
occurs O
by O
expansion O
, O
mitotic O
two O
in O
that O
followed O
suggest O
stages O
data O
expansion O
. O
a O
second O
the O
 
We O
premutation O
transmissions O
with O
. O
, O
, O
all O
to O
child O
informative O
father O
the O
carrier O
in O
expansion O
the O
that O
size O
also O
the O
notable O
show O
affected O
exception O
carrier O
decreases O
of O
. O
 
leukodystrophy I
mutation O
A O
not O
cause O
. O
does O
metachromatic B
of O
The O
R496H O
arylsulfatase O
 
MLD B
( O
. O
ARSA O
leukodystrophy I
of I
enzyme O
metachromatic B
) O
arylsulfatase I
Deficiency B
causes O
activity O
) O
( O
A I
 
for O
MLD B
mutations O
gene O
have O
. O
ARSA O
responsible O
identified O
number O
been O
of O
A O
 
R496H O
, O
1997 O
. O
. O
the O
) O
was O
to O
be O
proposed O
a O
Draghia O
MLD B
mutation O
al O
cause O
, O
et O
of O
( O
ARSA O
Recently O
of O
 
in O
this O
mutation O
at O
f O
have O
African O
0 O
= O
high O
. O
the O
= O
population O
( O
and O
frequency O
n O
R496H O
. O
, O
relatively O
We O
) O
subjects O
09 O
a O
American O
61 O
investigated O
an O
found O
mutation O
 
without O
and O
was O
. O
subjects O
normal O
mutation O
the O
activity O
R496H O
to O
in O
with O
be O
found O
determined O
and O
enzyme O
ARSA O
The O
 
ARSA O
not O
of O
of O
is O
negatively O
the O
is O
concluded O
R496H O
that O
does O
cause O
not O
activity O
a O
therefore O
It O
ARSA O
of O
MLD B
mutation O
and O
influence O
the O
 
carcinoma I
lines O
Down O
transgenes O
renal B
von B
regulation O
Hippel I
- O
by O
cell I
carbonic O
type O
in O
transmembrane O
wild O
. O
- O
anhydrases O
of O
Lindau I
- I
cell O
 
von B
Lindau I
- O
mediated O
stably O
transgenes O
carcinoma I
expressing O
lines O
- O
transfected O
) O
with O
used O
. O
genes O
cell O
involved O
renal B
- O
, O
we O
type O
discover O
carcinogenesis O
- I
VHL O
( O
To O
VHL B
in O
wild O
cell I
Hippel I
 
alpha O
several O
lines O
expressed O
large O
gene O
anhydrase O
technology O
. O
, O
an O
Scale O
these O
display O
genes O
CA12 O
carbonic O
differential O
including O
differentially O
RNA O
to O
identified O
termed O
applied O
- O
, O
cell O
 
- O
Deduced O
intact O
the O
pass O
protein O
CA O
was O
. O
apparently O
as O
classified O
catalytic O
module O
sequence O
the O
CA O
one O
extracellular O
domain O
an O
a O
possessing O
transmembrane O
in O
 
- O
CA12 O
the O
strongly O
the O
gene O
of O
carcinoma I
type O
the O
. O
parental O
VHL B
renal B
in O
cell I
Reintroduced O
lines O
overexpression O
wild O
cell O
inhibited O
 
catalytic O
. O
with O
transmembrane O
intact O
encoding O
CA9 O
obtained O
were O
similar O
with O
another O
, O
CA O
an O
domain O
Results O
 
could O
effectively O
regulate O
elongin O
domain O
protein O
of O
binding O
expression O
VHL B
although O
the O
of O
. O
the O
CA12 O
Both O
alone O
, O
CA9 O
to O
regulation O
domains O
contribute O
expression O
 
. O
mapped O
and O
to O
bands O
15q22 O
loci O
and O
We O
17q21 O
CA12 O
chromosome O
CA9 O
 
, O
in O
amplification O
some O
cancers B
to O
. O
prone O
respectively O
regions O
2 O
human O
 
define O
and O
of O
cancer B
CA O
IX O
XII O
role O
potential O
needed O
its O
experiments O
regulation O
in O
microenvironment O
. O
pH O
are O
and O
to O
enzymes O
the O
growth O
the O
in O
impact O
CA O
Additional O
extracellular O
on O
the O
cell O
of O
 
gene O
protein O
mutated O
transmembrane O
A O
atrophy I
mellitus I
syndrome I
) O
is O
Wolfram B
and O
. O
diabetes B
a O
optic B
in O
with O
( O
encoding O
patients O
 
young O
Wolfram B
recessive I
diabetes I
insulin B
222300 O
immune O
an O
syndrome I
atrophy I
dependent I
by O
onset O
- I
optic B
is O
OMIM O
; O
neurodegenerative I
and O
( O
progressive O
mellitus I
non O
- O
autosomal B
defined O
disorder I
. O
WFS B
) O
- O
 
linkage O
To O
on O
4p O
in O
five O
was O
markers O
chromosome O
. O
families O
confirmed O
 
a O
, O
of O
the O
/ O
to O
. O
P1 O
meiotic O
of O
BAC O
gene O
WFS B
than O
kb O
250 O
localized O
The O
less O
associated O
contig O
disease O
recombinants O
basis O
haplotypes O
was O
- O
and O
on O
 
, O
phenotype O
these O
a O
transmembrane O
affected O
with O
a O
families O
in O
and O
in O
putative O
WFS1 O
novel O
WFS B
mutations O
Mutations O
. O
found O
in O
disease O
were O
( O
associated O
encoding O
six O
individuals O
gene O
the O
protein O
) O
all O
were O
 
- O
and O
islet O
function O
in O
. O
neurons O
. O
survival O
beta O
WFS1 O
to O
of O
cells O
appears O
 
. O
in O
and O
tumor B
interaction O
and O
between O
the O
BRCA1 O
products O
the O
suppressor O
cells O
mitotic O
meiotic O
Stable O
genes O
BRCA2 O
of O
 
cancer I
hRAD51 O
and O
and O
and I
products O
breast B
account O
BRCA2 O
for O
onset O
, O
or I
early O
of O
familial O
most O
with O
encode O
each O
interact O
ovarian I
/ I
that O
BRCA1 O
. O
cases O
 
on O
foci O
presented O
in O
Results O
in O
here O
coexist O
somatic O
of O
a O
the O
BRCA2 O
subnuclear O
developing O
and O
elements O
. O
BRCA1 O
in O
and O
colocalize O
show O
and O
synaptonemal O
complexes O
cells O
biochemical O
complex O
that O
axial O
 
S O
of O
or O
following O
hydroxyurea O
like O
irradiation O
BRCA2 O
UV O
relocates O
And O
exposure O
. O
RAD51 O
+ O
phase O
replication O
sites O
to O
PCNA O
to O
cells O
, O
BRCA1 O
 
, O
recombination O
. O
BRCA2 O
pathway O
BRCA1 O
participate O
, O
, O
or O
break O
double O
and O
thus O
associated O
activation O
- O
the O
in O
and O
/ O
a O
( O
homologous O
with O
s O
together O
repair O
) O
of O
strand O
 
cancer I
majority O
of O
. O
pathway O
the O
cases O
be O
hereditary B
phenomenon O
this O
breast I
/ I
may O
in O
and I
a O
Of O
. O
ovarian I
dysfunction O
general O
or I
of O
 
and O
hydroxylase O
mRNA O
gene O
: O
CYP27 O
effects O
the O
- O
. O
splicing O
enzyme O
in O
a O
) O
Novel O
sterol O
27 O
mutation O
- O
on O
activity O
its O
( O
Arg362Ser O
pre O
 
to O
gene O
patient O
a O
cerebrotendinous B
identified O
by O
CYP27 O
A O
27 O
. O
hydroxylase O
the O
xanthomatosis I
with O
a O
sequencing O
gene O
( O
C O
from O
) O
CTX B
products O
CYP27 O
- O
( O
was O
sterol O
mutation O
amplified O
) O
in O
Novel O
 
of O
- O
residue O
expression O
( O
binding O
CGT O
responsible O
362Arg O
changed O
by O
362Arg O
cDNA O
and O
confirmed O
into O
27 O
the O
mutation O
the O
in O
for O
362Ser O
adrenodoxin O
mutant O
362Ser O
The O
deficiency O
) O
hydroxylase O
to O
. O
cofactor O
cells O
to O
- O
, O
activity O
sterol O
AGT O
1 O
, O
was O
as O
COS O
 
52 O
of O
Quantitative O
showed O
the O
represented O
mRNA O
analysis O
the O
gene O
CYP27 O
. O
patient O
that O
in O
expression O
 
5 O
. O
of O
% O
normal O
the O
level O
 
the O
the O
position O
6 O
splice O
normal O
. O
splicing O
alternative O
- O
As O
gene O
exon O
6 O
exon O
hypothesized O
- O
efficiency O
elsewhere O
, O
occurred O
that O
decreased O
the O
mutation O
exon O
of O
( O
in O
6 O
which O
the O
nucleotide O
site O
may O
in O
partially O
6 O
we O
transcript O
resulted O
affect O
the O
of O
) O
the O
intron O
and O
penultimate O
, O
mutation O
cause O
2 O
at O
of O
splicing O
in O
patient O
 
cryptic O
- O
at O
from O
the O
bp O
Of O
end O
transfection O
splice O
constructed O
5 O
COS O
88 O
into O
site O
3 O
for O
an O
species O
exon O
alternatively O
1 O
activated O
the O
a O
, O
, O
spliced O
responsible O
of O
cells O
upstream O
was O
mutant O
6 O
the O
that O
with O
without O
minigenes O
or O
minigene O
. O
mutation O
confirmed O
mRNA O
 
of O
CYP27 O
splicing O
that O
6 O
the O
penultimate O
pre O
27 I
leads O
data O
in I
gene O
activity I
sterol I
- I
hydroxylase I
alternative O
to O
, O
A O
the O
Our O
gene O
not O
of O
C O
deficiency B
nucleotide O
the O
but O
mRNA O
. O
only O
also O
of O
at O
- O
causes O
to O
partially O
suggest O
the O
exon O
the I
the O
mutation O
 
on O
the O
splicing O
knowledge O
effects O
a O
site O
to O
splice O
of O
2 O
pre O
Our O
a O
- O
regarding O
mRNA O
report O
position O
this O
5 O
is O
mutation O
of O
- O
. O
, O
first O
at O
the O
 
in O
. O
classical O
in O
ATM O
the O
patients O
population O
Dutch O
telangiectasia I
ataxia B
- I
germline O
mutations O
 
for O
mutations O
- I
( O
. O
are O
ataxia B
the O
disorder I
T I
telangiectasia I
A B
responsible O
- I
Germline O
recessive I
) O
autosomal B
the O
in O
gene O
ATM O
 
including O
mutation O
determined O
as O
T I
have O
A B
some O
we O
patients O
12 O
classical O
ATM O
our O
Dutch O
spectrum O
, O
- I
populations O
study O
origin O
, O
well O
, O
. O
in O
ethnic O
as O
of O
the O
immigrant O
19 O
In O
 
76 O
detection O
test O
and O
and O
compared O
% O
of O
method O
truncation O
. O
) O
fingerprinting O
respectively O
Both O
the O
were O
endonuclease O
, O
protein O
the O
efficiency O
% O
their O
and O
used O
( O
restriction O
( O
the O
mutations O
) O
PTT O
60 O
for O
, O
identifying O
REF O
 
be O
heterozygote O
patients O
to O
Most O
found O
were O
compound O
. O
 
. O
not O
distinct O
, O
which O
reported O
were O
previously O
10 O
Seventeen O
were O
of O
mutations O
 
are O
frequently O
small O
point O
splice O
sites O
affecting O
mutations O
deletions O
or O
. O
Mutations O
 
a O
Moreover O
, O
. O
16 O
 
two O
end O
the O
3 O
likely O
most O
7 O
of O
deletion O
result O
. O
was O
of O
between O
LINE O
- O
a O
identified O
of O
the O
recombination O
, O
elements O
kb O
genomic O
, O
gene O
 
mutation O
was O
mutation O
be O
A B
individuals O
identified O
to O
- I
in O
, O
described O
T I
A B
founder O
found O
frequently O
T I
The O
Turkish O
previously O
three O
Turkish O
. O
a O
- I
unrelated O
, O
most O
 
the O
frequency O
small O
Presence O
ethnic O
in O
indicate O
carrier O
founder O
in O
communities O
a O
a O
mutation O
relatively O
could O
among O
Western O
high O
groups O
Europe O
. O
of O
such O
population O
 
effect O
of O
could O
however O
in O
. O
be O
, O
identified O
ethnic O
, O
founder O
Patients O
no O
Dutch O
origin O
significant O
 
the O
including O
splice O
the O
. O
phenotype O
mutations O
heterogeneity O
- O
no O
genetic O
reflection O
percentage O
observed O
site O
relative O
on O
high O
The O
had O
of O
 
T I
cellular O
A B
and O
- I
. O
All O
increased O
radioresistant O
manifested O
DNA O
classical O
patients O
synthesis O
 
COL4A4 O
syndrome I
recessive I
of O
of O
causing O
the O
structure O
Of O
Alport I
mutations O
and O
the O
determination O
. O
novel O
gene O
autosomal B
genomic O
 
, O
COL4A3 O
syndrome I
alpha4 O
. O
associated O
mutations O
which O
membrane I
or O
hematuric B
basement I
type O
recessive I
the O
Autosomal B
characterized O
COL4A4 O
encode O
Alport I
is O
in O
IV O
respectively O
, O
alpha3 O
collagen O
chains O
gene O
a O
abnormalities I
and O
the O
progressive O
with O
by O
glomerular B
and O
the O
either O
glomerulonephritis I
 
the O
has O
screening O
hampered O
the O
been O
. O
genomic O
by O
lack O
Date O
in O
information O
structure O
, O
mutation O
of O
genes O
to O
two O
 
10 O
gene O
report O
Alport I
the O
the O
detection O
, O
comprehensive O
patients O
complete O
the O
, O
here O
syndrome I
the O
recessive I
autosomal B
of O
. O
of O
in O
diagnosed O
We O
gene O
and O
eight O
a O
of O
48 O
exons O
screen O
COL4A4 O
mutations O
characterization O
subsequent O
with O
novel O
 
is O
. O
carriers O
in O
a O
domain O
we O
, O
alanine O
, O
apparently O
silent O
in O
collagenous O
11 O
Furthermore O
in O
the O
to O
identified O
heterozygous O
substitution O
that O
the O
glycine O
 
individual O
substitution O
one O
% O
this O
5 O
glycine O
. O
, O
individuals O
all O
and O
control O
in O
of O
control O
homozygous O
for O
 
in O
obvious O
not O
There O
that O
has O
no O
individuals O
a O
previous O
. O
with O
any O
been O
phenotype O
homozygous O
is O
substitution O
of O
finding O
associated O
glycine O
 
French O
and I
BRCA1 O
in O
and O
Canadian O
cancer I
mutations O
ovarian I
breast B
founder O
BRCA2 O
families O
. O
 
/ I
BRCA2 O
Have O
ovarian I
Canadian O
families O
identified O
cancer I
in O
from O
in O
four O
, O
breast B
the O
BRCA1 O
French O
breast B
. O
genes O
mutations O
Quebec O
cancer I
breast B
each O
we O
- O
susceptibility O
cancer I
and O
of O
and O
, O
 
the O
, O
identify O
ascertained O
cancer B
families O
of O
we O
for O
French O
Canadian O
mutations O
examined O
these O
distribution O
eight O
founder O
effects O
independently O
To O
. O
 
41 O
found O
of O
Mutations O
were O
97 O
in O
families O
. O
 
Six O
. O
at O
eight O
of O
were O
mutations O
least O
observed O
twice O
 
mutation O
the O
The O
most O
followed O
BRCA2 O
, O
found O
was O
the O
common O
8765delAG O
mutation O
C4446T O
mutation O
. O
BRCA1 O
by O
 
identified O
41 O
a O
of O
, O
28 O
these O
were O
have O
. O
mutations O
to O
mutation O
found O
Together O
families O
in O
 
was O
BRCA1 O
mutations O
of O
of O
four O
any O
. O
detection O
the O
odds O
18 O
of O
The O
 
the O
also O
7x O
family O
one O
or O
cases O
present O
of O
greater O
. O
more O
were O
in O
ovarian B
cancer I
if O
 
mutations O
Odds O
of O
four O
the O
the O
of O
5 O
any O
. O
detection O
BRCA2 O
of O
was O
 
family O
the O
least O
Greater O
breast B
at O
if O
of O
in O
there O
were O
3x O
cancer I
cases O
. O
five O
 
age O
of O
presence O
years O
a O
of O
of O
mutations O
case O
36 O
breast B
strongly O
of O
of O
cancer I
presence O
The O
the O
. O
eight O
screened O
was O
, O
any O
< O
the O
predictive O
interestingly O
 
alleles O
families O
similar O
, O
the O
. O
mutation O
a O
be O
the O
, O
of O
descent O
indicating O
founder O
haplotypes O
mutant O
mutation O
shared O
in O
by O
for O
to O
same O
Carriers O
population O
likely O
the O
identical O
that O
from O
, O
were O
different O
 
and O
identification O
cancer I
will O
BRCA2 O
/ I
. O
common O
and O
of O
in O
breast B
detection O
facilitate O
mutations O
carrier O
cancer I
The O
breast B
ovarian I
families O
French O
BRCA1 O
Canadian O
 
in O
? O
impairment I
Dp71 O
Duchenne B
to O
cognitive B
and O
brain O
muscular I
dystrophy I
isoforms O
dystrophin O
related O
Are O
Dp140 O
 
performed O
order O
neuropsychological O
cognitive B
( O
explanation O
DMD B
Duchenne B
muscular I
DMD B
a O
the O
for O
molecular O
with O
impairment I
in O
patients O
Molecular O
to O
analysis O
dystrophy I
find O
patients O
most O
concurrently O
study O
observed O
) O
on O
in O
49 O
were O
and O
. O
 
. O
gene O
the O
DMD B
different O
relation O
of O
dystrophin O
complete O
Analysis O
promoters O
in O
deletions O
the O
the O
was O
define O
duplications O
and O
performed O
of O
to O
localization O
to O
 
Qualitative O
analysis O
specific O
testing O
for O
were O
and O
exon O
. O
out O
of O
the O
Dp71 O
the O
Dp140 O
carried O
also O
of O
transcript O
first O
 
reading O
, O
verbal O
and O
, O
neuropsychological O
Assessed O
intelligence O
. O
analysis O
verbal O
and O
memory O
visuospatial O
skills O
 
psychometric O
deletions O
cognitive B
of O
that O
molecular O
of O
. O
associated O
distal O
be O
part O
gene O
and O
the O
findings O
the O
duplications O
that O
preferentially O
impairment I
were O
demonstrated O
Comparison O
and O
to O
localized O
in O
with O
seemed O
 
in O
patients O
four O
Altered O
DNA O
and O
dysfunction I
cerebral B
. O
with O
Dp140 O
deleted O
two O
Dp71 O
transcripts O
two O
found O
severe O
were O
sequences O
 
part O
may O
be O
distal O
that O
and O
. O
expressed O
to O
cognitive B
, O
brain O
particular O
some O
impairment I
, O
with O
sequences O
the O
. O
associated O
DMD B
some O
in O
the O
DMD B
the O
gene O
related O
in O
Findings O
suggest O
of O
in O
isoforms O
located O
the O
these O
 
polyposis I
family O
hereditary B
a O
and O
mutations O
- I
I1307K O
with O
colorectal I
Jewish O
in O
hMLH1 O
APC O
cancer I
non I
. O
- O
non O
 
Describe O
HNPCC B
) O
hereditary B
hMLH1 O
polyposis I
Canadian O
truncating O
mutation O
a O
- I
we O
. O
carries O
kindred O
cancer I
( O
colorectal I
a O
non I
in O
novel O
which O
French O
 
Interestingly O
risk O
colorectal B
polymorphism O
, O
is O
cancer I
I1307K O
also O
with O
APC O
of O
an O
associated O
, O
, O
increased O
present O
. O
the O
in O
family O
this O
 
of O
previously O
identified O
self O
I1307K O
been O
has O
reported O
Ashkenazi O
Jewish O
origins O
polymorphism O
only O
- O
in O
individuals O
the O
. O
 
cancer B
, O
In O
between O
there O
or O
family O
relationship O
. O
, O
be O
presence O
the O
no O
appears O
polymorphism O
absence O
in O
. O
to O
of O
and O
addition O
the O
I1307K O
this O
 
the O
Japanese O
mutation O
. O
of O
coproporphyria I
novel O
of O
gene O
family O
a O
CPO O
a O
in O
hereditary B
Identification O
 
. O
gene O
characterized O
a O
in O
disease I
autosomal B
of I
dominant I
oxidase I
coproporphyria I
a O
coproporphyrinogen I
deficiency B
the O
CPO O
caused O
HCP B
by O
( O
) O
an O
Hereditary B
is O
) O
mutation O
CPO O
by O
( O
 
reported O
gene O
HCP B
11 O
of O
in O
have O
only O
the O
Mutations O
been O
patients O
. O
 
family O
another O
report O
mutation O
in O
a O
Japanese O
. O
We O
 
T O
C O
analyses O
and O
substitution O
to O
for O
polymerase O
, O
demonstrated O
polymorphism O
Chain O
strand O
gene O
at O
conformational O
a O
mitochondria O
in O
in O
the O
to O
which O
single O
- O
exon O
. O
lies O
85 O
reaction O
sequence O
targeting O
direct O
1 O
putative O
of O
nucleotide O
the O
position O
CPO O
presequence O
 
glutamine O
at O
the O
position O
changes O
a O
mutation O
codon O
amino O
for O
acid O
. O
codon O
termination O
This O
29 O
to O
 
showed O
in O
two O
family O
MaeI O
carriers O
the O
analysis O
restriction O
other O
. O
 
TIC O
TIC O
real O
rather O
alternative O
1 O
the O
within O
) O
- O
located O
putative O
is O
supporting O
, O
. O
that O
- O
. O
is O
The O
C O
than O
- O
proposed O
recently O
1 O
codon O
2 O
a O
( O
TIC O
TIC O
T O
- O
translation O
mutation O
initiation O
 
With O
uremic I
complement I
syndrome I
deficiency I
H I
hemolytic B
. O
factor I
associated O
Human B
 
protein I
cases O
regulatory I
Study O
renal I
acute B
context O
complement I
( O
this O
an O
human I
of O
FH O
Factor I
reports O
in O
six O
in I
disease I
on O
of O
H I
) O
the O
. O
deficiency B
the I
 
Of O
were O
( O
hemolytic B
) O
presenting O
five O
cases O
the O
in O
. O
with O
HUS B
children O
uremic I
idiopathic O
syndrome I
observed O
 
Two O
) O
- O
of O
by O
FHR O
the O
kD O
( O
like O
and O
- O
) O
characterized O
of O
related O
form O
homozygous O
- O
of O
, O
, O
- O
immunoblotting O
other O
protein O
kD O
the O
. O
1 O
absence O
FHL O
protein O
of O
the O
150 O
exhibited O
children O
- O
bands O
FH O
Factor O
and O
Factor O
a O
the O
upon O
H O
the O
H O
1 O
presence O
( O
42 O
deficiency O
 
large O
FH O
underlying O
deficiency O
deficiency O
with O
out O
as O
presence O
defect O
gene O
a O
of O
one O
and O
deletion O
for O
homozygous O
ruled O
. O
of O
PCR O
patient O
Blot O
DNA O
analysis O
the O
of O
southern O
the O
of O
the O
the O
 
other O
of O
presented O
FH O
the O
pattern O
The O
deficiency O
heterozygous O
family O
proteins O
children O
exhibited O
with O
four O
immunoblotting O
and O
normal O
a O
of O
. O
 
the O
only O
Factor B
deficiency I
deficiency I
. O
is O
complement B
HUS B
with O
associated O
H I
 
These O
for O
in O
suggest O
role O
/ O
observations O
FH O
and O
the O
FH O
HUS B
a O
or O
. O
of O
idiopathic O
. O
pathogenesis O
receptors O
 
ancient O
in O
population O
Further O
major O
Japanese O
the O
studies O
myotonic B
evidence O
disequilibrium O
. O
from O
a O
underlying O
linkage O
for O
dystrophy I
mutation O
 
n O
to O
a O
normal O
( O
DM B
) O
of O
chromosomes O
50 O
an O
5 O
unstable O
repeat O
but O
mutation O
copies O
. O
) O
is O
37 O
, O
3000 O
myotonic B
at O
The O
DM B
dystrophy I
- O
present O
CTG O
( O
amplified O
chromosomes O
on O
on O
copy O
- O
number O
repeats O
 
the O
Caucasian O
question O
events O
a O
molecular O
of O
findings O
DM B
in O
chromosome O
mutation O
a O
in O
. O
Previous O
involved O
about O
founder O
the O
expansion O
raise O
populations O
 
) O
haplotypes O
CTG O
markers O
region O
we O
mutation O
the O
( O
n O
founder O
and O
exists O
, O
repeat O
for O
in O
to O
near O
constructed O
polymorphic O
whether O
. O
chromosome O
DM B
genotyped O
a O
Investigate O
population O
the O
using O
Japanese O
families O
the O
 
were O
haplotype O
Six O
always O
found O
haplotypes O
alleles O
and O
. O
A O
were O
different O
DM B
 
. O
families O
130 O
origin O
90 O
unaffected O
population O
the O
to O
affected O
mechanism O
the O
members O
an O
the O
CTG O
mutation O
have O
of O
we O
of O
find O
studied O
Japanese O
190 O
DM B
expansion O
and O
in O
and O
To O
the O
mutation O
) O
comprising O
Japanese O
repeat O
( O
investigate O
n O
 
19 O
expansion O
mutations O
ancestral O
Caucasian O
suggest O
an O
Japanese O
have O
n O
Results O
by O
the O
to O
populations O
= O
ancestral O
common O
and O
a O
both O
5 O
n O
originated O
copies O
37 O
= O
in O
repeat O
that O
- O
. O
of O
few O
 
triplet O
that O
repeat O
support O
both O
Data O
. O
ataxia I
have O
for O
Friedreichs B
DM B
multistep O
proposed O
expansion O
. O
these O
and O
of O
been O
models O
 
. O
Africa O
The O
the O
C6 B
, O
Cape O
in O
molecular O
of O
basis O
South O
western O
deficiency I
 
Deficiency B
human I
of O
. O
, O
complement I
sixth I
number O
) O
component I
a O
has O
the I
reported O
from O
Africa O
Cape O
been O
of I
( O
of I
C6 O
families O
western O
in O
the O
South O
 
ascertained O
. O
is O
of O
Cape O
recurrent O
all O
disease I
C6Q0 O
( O
Meningococcal B
been O
disease O
almost O
because O
) O
in O
of O
pedigrees O
total O
and O
C6 B
endemic O
deficiency I
the O
have O
 
and O
gene O
and O
have O
1936delG O
in O
three O
is O
the O
the O
sequenced O
to O
. O
unreported O
hitherto O
defects O
total O
deficiency O
the O
expressed O
African O
which O
1195delC O
which O
common O
found O
reported O
leading O
C6 O
defect O
the O
from O
- O
and O
and O
, O
have O
exons O
We O
molecular O
cases O
have O
Cape O
879delG O
selected O
in O
, O
previously O
of O
been O
Americans O
, O
 
defects O
are O
, O
1195delC O
/ O
show O
the O
C7 O
we O
C6 O
DNA O
haplotypes O
associated O
characteristic O
that O
although O
small O
observed O
879delG O
variations O
and O
with O
marker O
Also O
region O
. O
were O
 
1936delG O
defect O
could O
only O
its O
. O
in O
be O
deduced O
was O
Cape O
associated O
The O
the O
but O
, O
haplotype O
once O
observed O
 
unrelated O
. O
the O
all O
studied O
C6Q0 O
the O
indicate O
from O
from O
Data O
for O
we O
defects O
38 O
these O
have O
account O
Cape O
individuals O
molecular O
the O
the O
in O
three O
haplotypes O
that O
defects O
the O
 
but O
the O
observed O
in O
- I
defect O
have O
not O
the O
879delG O
defect O
probably O
come O
in O
did O
from O
Dutch O
. O
, O
We O
C6 B
Cape O
. O
kindreds O
two O
The O
the O
deficient I
also O
Netherlands O
879delG O
 
: O
further O
C7 I
seven O
molecular O
. O
marker O
and O
associated O
haplotypes O
Complement B
defects O
their O
deficiency I
 
C7 B
described O
Further O
are O
seven O
. O
molecular O
of O
bases O
deficiency I
 
codons O
and O
these O
single O
, O
- O
, O
deletions O
of O
molecular O
involve O
some O
defects O
All O
new O
, O
others O
sites O
. O
and O
nucleotide O
splice O
which O
alter O
substitutions O
events O
 
end O
but O
, O
. O
the O
gene O
towards O
predominantly O
they O
along O
the O
distributed O
3 O
Are O
C7 O
 
in O
All O
heterozygous O
. O
were O
compound O
individuals O
found O
 
are O
. O
most O
. O
marker O
C7 O
associated O
tabulated O
C7 B
the O
with O
defects I
C6 O
/ O
haplotypes O
 
to O
wellness O
for O
Genome O
the O
affective I
search O
disorder I
loci O
for O
health O
Amish O
among O
a O
risk O
bipolar B
wide O
. O
Order O
- O
relatives O
in O
mental O
linked O
chromosomal O
at O
high O
Old O
 
BPAD B
of O
and O
periods O
Characterized O
disorder I
) O
by O
depression B
Bipolar B
hypomania B
depressive I
; O
illness I
. O
episodes O
interspersed O
is O
/ O
affective I
with O
- I
or O
of O
mania B
manic B
( O
 
genetic O
susceptibility O
to O
develop O
. O
supports O
in O
a O
Compelling O
evidence O
the O
component O
BPAD B
significant O
 
or O
however O
attempted O
loci O
chromosomal O
to O
cause O
identify O
the O
risk O
developing O
to O
, O
BPAD B
have O
that O
only O
Date O
. O
studies O
linkage O
of O
increase O
, O
 
developing O
determine O
Amish O
of O
of O
) O
there O
protective O
mental O
wide O
to O
our O
multigeneration O
extremely O
Whether O
BPAD B
to O
in O
other O
Old O
, O
be O
the O
similar O
linkage O
several O
reduce O
, O
risk O
alleles O
an O
in O
is O
used O
- O
pedigrees O
high O
observed O
prevent O
BPAD B
psychiatric B
( O
of O
any O
large O
as O
wellness O
disorder I
Order O
absence O
incidence O
genetic B
that O
. O
the O
health O
we O
disorders I
what O
genome O
exhibiting O
could O
or O
scan O
phenotype O
of O
 
= O
( O
at O
2 O
a O
locus O
4 O
4q O
linkage O
; O
on O
Pempirical O
evidence O
< O
22 O
x O
for O
( O
x O
05 O
D4S2949 O
have O
57 O
locus O
score O
. O
( O
10 O
P O
P O
nonparametric O
- O
. O
) O
( O
- O
= O
( O
- O
linkage O
PLUS O
29 O
on O
suggestive O
chromosome O
strong O
value O
found O
10 O
score O
nonparametric O
4p O
maximum O
and O
GENEHUNTER O
= O
, O
maximum O
chromosome O
. O
3 O
D4S397 O
PLUS O
for O
) O
5 O
- O
10 O
. O
SIBPAL O
a O
) O
at O
5 O
3 O
evidence O
4 O
3 O
x O
, O
We O
- O
GENEHUNTER O
= O
 
SIBPAL O
1 O
( O
mental O
linked O
are O
) O
health O
value O
. O
3 O
Pempirical O
to O
that O
) O
wellness O
- O
; O
x O
10 O
< O
) O
 
consistent O
clinical O
are O
alleles O
prevent O
hypothesis O
or O
other O
manifestations O
of O
certain O
the O
could O
related O
disorders I
with O
affective B
modify O
. O
that O
These O
findings O
perhaps O
and O
BPAD B
the O
 
. O
segregation O
in O
Distortion O
myotonic B
dystrophy I
 
) O
DM B
generation O
dominant I
is O
pedigree O
a O
an O
three O
cascade O
( O
in O
dystrophy I
which O
the O
. O
autosomal B
typical O
, O
shows O
, O
Myotonic B
disease I
anticipation O
 
this O
that O
the O
( O
infertility B
of O
dystrophy I
with O
disappearance O
myotonic I
DM B
) O
pedigree O
CDM B
. O
Results O
in O
and O
congenital B
in O
 
segregation O
locus O
is O
DM B
concept O
DM B
where O
the O
in O
of O
, O
explain O
the O
larger O
, O
of O
population O
been O
The O
forward O
there O
at O
. O
to O
has O
the O
the O
transmission O
of O
put O
partially O
preferential O
distortion O
maintenance O
allele O
 
59 O
of O
were O
a O
, O
. O
in O
DM B
Northern O
pedigrees O
In O
ascertained O
Ireland O
survey O
 
had O
status O
their O
to O
were O
the O
to O
been O
of O
determine O
the O
offspring O
examined O
the O
where O
DM B
transmission O
Sibships O
from O
of O
affected O
parents O
all O
identified O
the O
expansion O
members O
. O
 
, O
58 O
male O
where O
. O
transmitting O
parent O
was O
The O
 
3 O
. O
were O
female O
of O
, O
68 O
affected O
offspring O
the O
, O
a O
in O
% O
the O
transmitting O
case O
and O
of O
parent O
 
% O
were O
. O
affected O
7 O
 
at O
the O
the O
. O
meiotic O
in O
have O
DM O
allele O
locus O
- O
studies O
DM B
for O
CTGn O
On O
of O
non O
in O
increased O
heterozygotes O
larger O
shown O
drive O
DM B
transmission O
 
be O
that O
provides O
preferentially O
the O
tends O
DM B
study O
. O
transmitted O
expansion O
evidence O
to O
further O
This O
 
. O
diagnosis O
Of O
hemochromatosis B
 
death I
the O
under O
untreated O
. O
can O
disease O
and O
illness O
, O
serious O
hemochromatosis B
If O
, O
cause O
diagnosed O
- O
is O
but O
substantially O
early B
still O
 
level O
transferrin O
serum O
case O
screening O
. O
detection O
ferritin O
the O
the O
saturation O
is O
and O
the O
serum O
measurement O
of O
Cornerstone O
of O
and O
 
liver O
physicians O
, O
overload I
levels O
to O
biopsy O
use O
. O
suspected O
specimens O
the O
Once O
presence O
ferritin O
iron O
must O
serum O
the O
and O
stores O
on O
is O
for O
hepatic O
iron B
patients O
diagnosis O
assess O
of O
 
Liver O
of O
biopsy O
absence O
, O
which O
affect O
and O
used O
or O
to O
presence O
. O
management O
cirrhosis B
can O
is O
also O
prognosis O
establish O
the O
 
being O
- O
still O
test O
its O
the O
based O
DNA O
for O
evaluated O
is O
A O
in O
but O
HFE O
available O
the O
hemochromatosis B
is O
commercially O
of O
diagnosis O
, O
. O
gene O
place O
 
disease O
role O
the O
is O
family O
most O
hemochromatosis B
test O
of O
the O
case O
a O
for O
in O
this O
proven O
of O
, O
the O
the O
with O
detection O
useful O
Currently O
members O
patients O
of O
. O
in O
 
can O
hemochromatosis B
and O
can O
crucial O
. O
It O
hepatic B
cirrhosis I
before O
phlebotomy O
even O
diagnose O
to O
disease O
life O
expectancy O
to O
chronic O
therapy O
is O
. O
avert O
normal O
serious O
because O
lead O
develops O
 
variant O
APC B
for O
cancer I
origin O
risk O
. O
I1307K O
the O
of O
and O
Israeli O
in O
colorectal B
Prevalence O
Jews O
differing O
ethnic O
of O
gene O
 
highest O
European O
. O
ethnic O
. O
of O
Jews O
colorectal B
e O
i O
& O
, O
Ashkenazim O
, O
Israeli O
have O
, O
cancer I
AIMS O
. O
BACKGROUND O
Israeli O
birth O
the O
incidence O
group O
of O
any O
 
the O
in O
APC B
I1307K O
was O
found O
gene O
variant O
6 O
. O
 
cases O
colorectal B
28 O
, O
of O
of O
% O
% O
, O
their O
cancer I
Jews O
non O
but O
familial O
- O
Jews O
1 O
in O
. O
not O
American O
 
colorectal B
the O
risk O
assessed O
. O
and O
prevalence O
ethnic O
in O
origin O
cancer I
for O
I1307K O
Jews O
differing O
of O
We O
Israeli O
 
method O
by O
European O
from O
I1307K O
the O
or O
for O
) O
with O
specific O
of O
a O
, O
ASO O
. O
history O
were O
/ O
( O
- O
variant O
non O
family O
without O
, O
500 O
METHODS O
or O
origin O
or O
personal O
neoplasia B
unrelated O
and O
allele O
oligonucleotide O
Jews O
of O
DNA O
the O
samples O
- O
European O
examined O
 
In O
. O
for O
risk O
persons O
I1307K O
, O
cancer I
in O
colorectal B
at O
5 O
found O
RESULTS O
was O
average O
 
1 O
and O
. O
Of O
120 O
% O
0 O
European O
 
% O
0 O
- O
08 O
6 O
Jews O
Of O
= O
. O
( O
) O
P O
188 O
. O
European O
non O
 
15 O
Occurred O
. O
it O
in O
 
4 O
cancer B
02 O
of O
52 O
= O
Ashkenazi O
Jews O
. O
and O
risk O
with O
0 O
. O
increased O
% O
detected O
not O
51 O
European O
Israelis O
- O
( O
familial O
non O
P O
was O
cancer B
) O
in O
at O
 
neoplasia I
families O
occurred O
of O
, O
carriers O
family O
or O
Ashkenazi O
or O
20 O
I1307K O
of O
history O
. O
of O
8 O
the O
of O
had O
whom O
13 O
Colorectal B
personally O
in O
also O
neoplasia B
personal O
noncolonic O
a O
 
cancer I
CONCLUSIONS O
The O
and O
or I
in O
Jews O
may O
Ashkenazi O
the O
incidence O
in O
cancers I
for O
other I
susceptibility O
European O
variant O
higher O
. O
partially O
of O
Israelis O
represent O
a O
, O
I1307K O
, I
colorectal B
explains O
, I
APC O
colorectal B
gene O
 
. O
hereditary B
gene O
analysis O
coproporphyria I
oxidase O
in O
Of O
defects O
update O
coproporphyrinogen O
and O
mutation O
systematic O
 
coproporphyria I
is O
coproporphyrinogen I
autosomal O
) O
activity I
by O
) O
an O
dominant O
caused O
inheritance O
deficient B
acute O
( O
CPO O
Hereditary B
III I
oxidase I
with O
( O
HC B
hepatic B
of I
. O
porphyria I
 
precipitated O
Manifestations O
diseases I
, O
of O
clinical O
, O
changes O
by O
often O
infectious B
. O
hormonal O
or O
dysfunction I
cyclical O
acute O
fasting O
attacks O
neurological B
characterized O
drugs O
by O
disease O
are O
, O
the O
of O
 
also O
may O
Skin O
photosensitivity O
. O
be O
present O
 
by O
from O
DGGE O
part O
and O
exon O
denaturing O
by O
3 O
by O
, O
heterozygous O
electrophoresis O
gene O
- O
CPO O
followed O
the O
Holland O
the O
France O
in O
unrelated O
sequence O
, O
patients O
- O
exon O
boundaries O
noncoding O
gradient O
Seven O
direct O
systematically O
of O
exons O
exon O
the O
gel O
) O
intron O
Czech O
, O
strategy O
of O
( O
analyzed O
and O
an O
HC B
were O
/ O
sequencing O
seven O
. O
Republic O
 
and O
new O
two O
detected O
Seven O
. O
mutations O
novel O
were O
polymorphisms O
 
( O
site O
a O
two O
15c O
. O
a O
, O
nonsense O
is O
mutations O
mutation O
two O
new O
W427R O
missense O
( O
a O
These O
- O
which O
acceptor O
1168del3bp O
) O
and O
are O
> O
; O
position O
, O
splicing O
splice O
Q306X O
Q385X O
at O
) O
small O
glycine O
- O
662de14bp O
g O
, O
, O
IVS1 O
( O
two O
) O
( O
among O
- O
creates O
, O
390 O
) O
deletions O
G197W O
one O
are O
removing O
are O
 
site O
- O
respective O
390delGly O
using O
expression O
the O
G197W O
point O
- O
in O
. O
of O
, O
and O
, O
deletion O
W427R O
Pathological O
mutations O
the O
by O
significance O
system O
in O
assessed O
the O
their O
frame O
prokaryotic O
were O
mutagenesis O
directed O
a O
 
resulted O
the O
or O
of O
absence O
. O
activity O
dramatic O
CPO O
mutations O
in O
These O
a O
decrease O
 
+ O
polymorphisms O
and O
bp O
bp O
two O
the O
6 O
noncoding O
( O
1 O
G O
) O
in O
base O
C O
deletion O
in O
G O
a O
downstream O
noncoding O
/ O
. O
region O
) O
the O
initiation O
of O
574 O
the O
- O
of O
of O
part O
last O
the O
/ O
a O
) O
) O
the O
bp O
574 O
localized O
in O
of O
polymorphism O
142C O
normal O
( O
codon O
, O
, O
transcriptional O
delATTCTT O
gene O
site O
from O
termination O
3 O
part O
2 O
the O
polymorphism O
the O
were O
upstream O
promotor O
gene O
142 O
CPO O
, O
The O
 
degree O
different O
now O
the O
dimorphisms O
allelic O
. O
and O
is O
so O
. O
well O
high O
defects I
seven O
are O
mutations O
far O
making O
in O
new O
nineteen O
Five O
of O
reported O
heterogeneity O
with O
gene B
of O
CPO O
demonstrated O
HC B
a O
intragenic O
total O
characterized O
 
within O
basis O
> O
A O
459 O
novel O
. O
two O
heterogeneity O
1G O
: O
alleles O
coincidence O
leukodystrophy I
metachromatic B
a O
of O
A O
and O
with O
+ O
mutation O
molecular O
Of O
family O
phenotypic O
arylsulfatase O
 
leukodystrophy I
GS O
( O
with O
) O
with O
and O
( O
three O
at O
) O
increased O
) O
In O
siblings O
, O
a O
A O
, O
deficient O
arylsulfatase O
5 O
fatal O
one O
infantile O
developed O
metachromatic B
galactosylsulfatide O
late O
ARSA O
, O
activity O
excretion O
age O
classical O
years O
. O
MLD B
( O
family O
 
, O
other O
12 O
well O
and O
/ O
apparently O
2 O
at O
MLD B
father O
1 O
within O
) O
, O
years O
respectively O
( O
patients O
of O
healthy O
siblings O
presented O
, O
, O
ARSA O
, O
values O
healthy O
GS O
The O
15 O
as O
and O
their O
the O
range O
. O
apparently O
two O
and O
 
mutations O
different O
Screening O
the O
. O
sequence O
ARSA O
heterogeneity O
intrafamilial O
basis O
phenotypic O
and O
disclosed O
being O
mutation O
three O
analysis O
the O
involvement O
molecular O
of O
of O
 
459 O
guanine O
. O
from O
7 O
of O
a O
in O
at O
- O
The O
> O
) O
mutation O
novel O
1 O
, O
inherited O
exon O
nucleotide O
( O
infantile O
7delG O
late O
single O
from O
patient O
1G O
type O
his O
, O
+ O
basepair O
0 O
frequent O
mother O
father O
microdeletion O
the O
and O
A O
his O
 
at O
of O
, O
clinically O
) O
their O
+ O
to O
8 O
two O
novel O
paternal O
on O
2435 O
substitution O
459 O
exon O
cytosine O
maternal O
the O
allele O
thymidine O
unaffected O
by O
siblings O
transition O
carried O
A O
A464V O
464 O
alanine O
, O
mutation O
1G O
a O
> O
( O
in O
valine O
The O
resulting O
and O
, O
nucleotide O
in O
. O
 
thus O
The O
was O
genotype O
/ O
. O
A464V O
7delG O
fathers O
 
and O
controls O
patients O
A464V O
. O
18 O
unrelated O
found O
MLD B
in O
was O
Mutation O
not O
50 O
 
ARSA O
mimicking O
manifestation O
, O
bears O
, O
clinical O
and O
frequent O
pseudodeficiency O
of O
A464V O
apparently O
modifying O
MLD B
the O
levels O
ARSA O
. O
although O
allele O
GS O
, O
significance O
little O
clearly O
for O
 
and O
serious O
that O
Results O
ARSA O
certain O
- O
values O
not O
, O
implications O
prognostic O
finding O
GS O
conditions O
MLD B
with O
clinical O
diagnostic O
our O
need O
and O
disease O
a O
. O
by O
genetic O
in O
be O
like O
demonstrate O
paralleled O
 
outbreak O
with O
but O
exist O
0 O
mutations O
not O
might O
- O
may O
disease O
, O
Moreover O
, O
the O
pathological O
of O
ARSA O
functionally O
levels O
. O
cause O
alleles O
clinical O
together O
A464V O
and O
GS O
type O
which O
. O
similar O
further O
ARSA O
, O
to O
, O
 
to O
and O
predisposes O
neurofibromatosis B
deficiency O
hematological B
malignancy I
. O
1 I
type I
MLH1 O
Human O
 
mutations O
DNA O
lead O
heterozygous O
genes O
to O
Germ O
colorectal I
nonpolyposis I
mismatch O
in O
cancer I
the O
repair O
line O
. O
- O
hereditary B
 
. O
both O
disease O
alleles O
is O
individuals O
The O
- O
who O
unknown O
type O
constitutionally O
lack O
susceptibility O
of O
wild O
 
signs O
hematological B
1 I
of O
) O
them O
a O
have O
at O
three O
NF1 B
nonpolyposis I
neurofibromatosis B
We O
type I
in O
two O
a O
offspring O
. O
identified O
very O
at O
family O
and O
early O
, O
displayed O
who O
colorectal I
hereditary B
age O
developed O
( O
cancer I
least O
malignancy I
of O
 
specific O
C676T O
sequence O
- O
analysis O
( O
> O
) O
. O
Arg226Stop O
- O
mutation O
in O
revealed O
two O
DNA O
MLH1 O
a O
- O
amplification O
homozygous O
siblings O
and O
allele O
 
MLH1 O
with O
repair O
. O
mismatch O
results O
. O
leukemia B
deficiency O
phenotype O
and O
by O
neurofibromatosis B
consequent O
and O
Thus O
a O
lymphoma B
a O
- O
mutator O
1 I
type I
or O
associated O
line O
/ O
, O
characterized O
in O
mutation O
homozygous O
germ O
 
PAX6 O
of O
. O
congenital B
most O
human O
mutations O
underlie O
eye I
the O
in O
of O
domain O
spectrum O
ancient O
the O
a O
paired O
residues O
malformations I
Missense O
 
of I
aniridia B
of O
underlie O
the I
the O
absence I
of I
eye I
a O
the I
PAX6 O
dominant O
iris I
Mutations O
. O
) O
human O
malformation B
( O
rare O
gene O
congenital B
, O
 
% O
of O
2 O
, O
just O
truncation O
) O
substitution O
and O
. O
PAX6 O
, O
mutations O
is O
( O
aniridia B
all O
patients O
spectrum O
of O
another O
the O
leading O
amino O
% O
one O
and O
by O
missense O
( O
) O
in O
reported O
insertions O
92 O
protein O
highly O
, O
premature O
leading O
of O
acid O
nonsense O
to O
The O
of O
deletions O
to O
biased O
with O
splicing O
mutations O
 
though O
should O
PAX6 O
the O
mutations O
they O
. O
patients O
common O
in O
hardly O
the O
seen O
missense O
amongst O
fact O
vertebrates O
pathological O
Extraordinary O
of O
predicts O
are O
ever O
at O
conservation O
amino O
in O
even O
protein O
the O
that O
be O
level O
aniridia B
acid O
 
distinct O
. O
ascertainment O
textbook O
is O
that O
indicates O
may O
mutation O
This O
bias O
analysis O
of O
and O
the O
aniridia B
PAX6 O
missense O
that O
selection O
for O
underlie O
patients O
the O
phenotypes O
from O
missing O
there O
mutations O
frequently O
in O
PAX6 O
heavy O
a O
 
mutations O
in O
present O
association O
and O
two O
here O
PAX6 O
) O
searching B
with O
( O
aniridia B
association O
phenotypes O
missense O
with O
and O
displaced B
two O
) O
congenital B
more O
phenotypes O
pupillae I
. O
pupils I
nystagmus I
gaze I
novel O
We O
, O
in O
( O
ectopia B
atypical O
, O
recognizable O
four O
 
known O
the O
within O
paired O
all O
located O
domain O
mutations O
are O
all O
and O
. O
domain O
four O
are O
paired O
PAX6 O
proteins O
Strikingly O
conserved O
highly O
affect O
, O
in O
which O
acids O
amino O
 
related I
substantial O
to O
bias O
results O
remains O
by O
hypothesis O
under O
representation O
ascertainment O
missense O
- O
the O
Our O
that O
that O
and O
uncovered O
PAX6 B
support O
- I
. O
is O
of O
. O
caused O
the O
disease I
mutations O
of O
suggest O
a O
burden O
be O
 
second I
deficiency B
of I
The O
factor O
component I
controlling O
major O
. O
chromosomal O
complement I
genes O
, O
complex O
properdin O
the I
B O
the O
of I
, O
order O
and O
histocompatibility O
of O
 
for O
genes O
the I
disorders O
the O
B O
( O
those O
HLA O
second I
patients O
C2 O
) O
coding O
deficiency B
for O
Factor O
coding O
families O
of I
for O
tissue O
in O
component I
properdin O
complement I
relationship O
studied O
of O
connective O
was O
to O
. O
of I
with O
The O
and O
of O
allotypes O
 
because O
. O
deficiency I
Were O
or O
patients O
were O
C2 B
homozygous O
selected O
heterozygous O
they O
for O
 
deficiency I
12 O
found O
were O
. O
informative O
matings O
for O
15 O
C2 B
families O
with O
 
with O
HLA O
recombinant O
57 O
. O
of O
crossovers O
two O
C2 B
and O
, O
between O
, O
the O
Of O
0 O
noted O
were O
informative O
gene O
fraction O
- O
gene O
a O
meioses O
deficiency I
the O
B O
 
. O
035 O
 
lod O
recombinant O
was O
likelihood O
HLA O
and O
a O
calculated O
a O
value O
for O
fraction O
B O
of O
of O
C2 B
of O
0 O
at O
linkage O
maximum O
- O
. O
Score O
the O
between O
13 O
deficiency I
 
04 O
. O
 
for O
properdin O
both O
HLA O
- O
B O
B O
21 O
Factor O
18 O
were O
. O
found O
families O
and O
informative O
allotype O
matings O
with O
 
were O
, O
a O
72 O
. O
giving O
, O
Informative O
of O
found O
0 O
of O
recombinants O
fraction O
three O
meioses O
recombinant O
 
. O
042 O
 
likelihood O
Factor O
maximum O
- O
Lod O
. O
of O
the O
B O
HLA O
was O
allotypes O
16 O
at O
0 O
a O
recombinant O
of O
calculated O
a O
between O
and O
B O
value O
fraction O
of O
score O
 
04 O
. O
 
B O
. O
A O
was O
A O
for O
, O
D O
- O
have O
genes O
occurred O
- O
D O
to O
between O
B O
shown O
which O
and O
HLA O
Factor O
in O
with O
and O
HLA O
segregared O
crossover O
HLA O
- O
 
that O
C2 B
close O
HLA O
lack O
, O
, O
that O
these O
5 O
suggests O
B O
another O
in O
that O
HLA O
- O
located O
HLA O
, O
approximately O
and O
deficiency I
C2 B
, O
that O
of O
genese O
one O
B O
allotype O
genes O
, O
outside O
These O
the O
the O
proximity O
, O
Factor O
the O
deficiency I
HLA O
A O
allotypes O
and O
gene O
deficiency I
B O
B O
studies O
D O
C2 B
genes O
recombinants O
- O
. O
genes O
for O
suggest O
deficiency I
that O
Factor O
Factor O
order O
and O
centimorgans O
those O
from O
B O
A O
to O
are O
, O
between O
C2 B
of O
B O
- O
loci O
lie O
the O
and O
and O
Factor O
- O
two O
- O
- O
for O
are O
- O
for O
the O
3 O
coding O
apparent O
gene O
is O
the O
 
implications O
dystrophy I
emerin O
in O
muscular I
heart O
and O
Emery B
. O
Dreifuss I
and O
distribution O
lamins O
Of O
for O
- I
the O
 
nuclear O
is O
is O
defective O
EDMD B
in O
missing O
. O
membrane O
Emery B
dystrophy I
protein O
- I
) O
which O
or O
muscular I
a O
Dreifuss I
( O
Emerin O
 
family O
Is O
receptor O
- O
LAP2 O
( O
and O
proteins O
member O
lamina O
of O
it O
associated O
a O
of O
one O
lamin O
LAP1 O
. O
includes O
) O
, O
B O
which O
LBR O
 
emerin O
panel O
of O
localize O
specific O
rabbit O
phage O
human O
molecule O
antibodies O
and O
been O
16 O
in O
has O
emerin O
mapped O
used O
using O
A O
to O
displayed O
( O
- O
has O
throughout O
peptide O
six O
) O
. O
the O
libraries O
mAbs O
monoclonal O
to O
been O
heart O
and O
sites O
 
, O
Several O
though O
recognized O
mAbs O
discs O
strongly O
, O
against O
at O
or O
spots O
recognize O
. O
the O
epitopes O
not O
did O
the O
in O
nuclei O
intercalated O
emerin O
rim O
they O
intranuclear O
and O
channels O
different O
in O
cardiomyocyte O
heart O
both O
 
on O
but O
emerin O
recognize O
. O
only O
blot O
membrane O
polyclonal O
after O
purification O
, O
a O
membrane O
and O
affinity O
pure O
a O
it O
stained O
- O
against O
did O
rabbit O
antiserum O
the O
against O
, O
band O
intercalated O
emerin O
western O
discs O
nuclear O
A O
both O
nuclear O
 
EDMD B
doubt O
that O
results O
, O
discs O
therefore O
in O
immunostaining O
due O
product O
gene O
of O
These O
emerin O
, O
of O
the O
absence O
be O
discs O
from O
would O
defects I
and O
caused O
. O
to O
some O
at O
intercalated O
the O
cast O
emerin O
intercalated O
cardiac B
by O
upon O
hypothesis O
a O
are O
expected O
not O
were O
if O
 
was O
. O
from O
although O
was O
it O
the O
- O
non O
heart O
Emerin O
nuclei O
of O
in O
many O
abundant O
, O
in O
cardiomyocyte O
absent O
cells O
the O
membranes O
myocyte O
 
to O
similar O
this O
an O
lamin O
of O
EDMD B
was O
Distribution O
candidate O
form O
A O
that O
, O
gene O
of O
of O
emerin O
autosomal O
for O
. O
a O
 
for O
cardiomyocyte O
lamin O
from O
of O
B1 O
not O
contrast O
lamin O
In O
localization O
to O
essential O
that O
B1 O
nuclei O
showing O
emerin O
, O
nuclear O
absent O
was O
is O
, O
lamina O
the O
. O
 
muscle O
is O
nuclei O
almost O
lamin O
also O
from O
completely O
absent O
skeletal O
B1 O
. O
 
, O
why O
particularly O
which O
absence O
emerin O
. O
. O
from O
heart O
and O
EDMD B
of O
additional O
already O
tissues O
offer O
nuclei O
an O
B1 O
lack O
lamin O
the O
of O
explanation O
these O
alternative O
affected O
In O
muscle O
skeletal O
may O
are O
 
region O
Bedlington O
chromosome O
the O
toxicosis I
in O
to O
genetic O
Mapping O
, O
2p13 O
in O
p16 O
human O
of O
syntenic O
to O
copper B
chromosome O
. O
region O
10 O
locus O
a O
terriers O
dog O
- O
 
as O
, O
recognized O
disorder I
copper I
rat O
an O
dog O
in O
accumulation I
, O
Is O
hepatic B
mouse O
. O
man O
abnormal O
inherited B
and O
 
Major O
accumulation I
copper I
WD B
the O
hepatic B
( O
Wilson B
of O
causing O
dysfunctional O
man O
a O
) O
, O
is O
in O
disease I
ATP7B O
gene O
. O
cause O
 
rat O
also O
genes O
have O
mouse O
Mutations O
demonstrated O
. O
and O
in O
in O
the O
been O
ATP7B O
 
human O
copper B
overload I
ATP7B O
The O
rarer O
been O
the O
childhood I
cirrhosis I
non B
gene O
Indian I
in O
genetic O
. O
- I
disease O
heterogeneity O
much O
, O
indicating O
excluded O
has O
 
disease I
Bedlington O
in O
copper B
the O
( O
locus O
new O
CT B
. O
toxicosis I
) O
autosomal O
in O
identified O
recessive O
progressive O
By O
a O
liver B
investigating O
we O
common O
have O
terriers O
involved O
, O
 
co O
CT B
WD B
in O
was O
whether O
C04107 O
gene O
causative O
the O
examined O
also O
by O
( O
. O
ATP7B O
We O
and O
FISH O
) O
- O
hybridization O
the O
chromosomal O
fluorescence O
for O
localization O
situ O
of O
investigating O
ATP7B O
using O
, O
 
is O
anonymous O
an O
CT B
linked O
microsatellite O
marker O
to O
. O
C04107 O
closely O
 
WD B
that O
to O
and O
chromosome O
clones O
respectively O
can O
to O
regions O
and O
CFA10q26 O
, O
be O
canine O
However O
CFA22q11 O
not O
demonstrating O
the O
. O
ATP7B O
C04107 O
containing O
mapped O
BAC O
, O
CT B
, O
homologous 
 
to O
also O
as O
they O
Transport O
since O
for O
genes O
region O
genes O
CTR2 O
. O
excluded O
candidate O
copper O
the O
chromosome O
mapped O
both O
were O
CT B
canine O
CFA11q22 O
and O
CTR1 O
 
2 O
- O
. O
22 O
 
. O
5 O
 
containing O
p16 O
a O
sequence O
. O
C04107 O
, O
found O
gene O
positional O
expressed O
identified O
from O
a O
genes O
the O
BAC O
homologous O
- O
chromosome O
to O
transcribed O
was O
- O
candidate O
be O
A O
any O
region O
to O
2p13 O
human O
of O
devoid O
from O
 
Analysis O
in O
- O
APC B
evidence O
gene O
in O
acid O
colorectal B
the O
extended O
genotype O
role O
the O
correlations O
changes O
phenotype O
of O
for O
FAP B
in O
cancer I
amino O
: O
. O
205 O
predisposition O
of O
families O
and O
molecular O
APC B
 
APC B
/ O
familial B
dominant O
FAP B
) O
of O
adenomatous I
a O
gene O
result O
of O
is O
coli I
mutations O
polyposis I
( O
extracolonic O
of O
the O
cancer I
The O
) O
development O
and O
BACKGROUND O
of O
inheritance O
range O
polyposis I
colorectal B
variable O
manifestations O
the O
. O
adenomatous B
( O
AIMS O
in O
 
in O
nine O
colorectal B
. O
for O
performed O
phenotype O
analysis O
study O
in O
to O
manifestations O
This O
incidence O
mutations O
the O
APC B
FAP O
- O
non O
correlations O
determine O
extracolonic O
mutation O
was O
investigate O
and O
the O
of O
of O
to O
genotype O
- O
direct O
APC B
gene O
cancer I
, O
 
in O
denaturing O
analysed O
FAP B
15 O
sequencing O
gene O
test O
using O
truncation O
gradient O
190 O
the O
was O
and O
patients O
The O
, O
and O
. O
FAP O
electrophoresis O
cancer I
APC B
- O
unrelated O
gel O
non O
METHODS O
colorectal B
direct O
, O
protein O
 
( O
RESULTS O
in O
. O
patients O
group O
) O
to O
Chain O
belonging O
identified O
the O
only O
were O
105 O
patients O
terminating O
FAP B
signals O
 
belonged O
colorectal B
whom O
acid O
three O
Amino O
- O
FAP O
patients O
of O
of O
. O
four O
the O
in O
patients O
identified O
non O
to O
changes O
, O
group O
were O
cancer I
 
- O
to O
genotype O
extracolonic O
in O
nature O
patients O
three O
correlations O
FAP B
identified O
belonging O
the O
of O
manifestations O
Phenotype O
mutation O
significant O
certain O
. O
in O
subgroups O
differences O
 
with O
potential O
mutations O
have O
the O
threatening O
conditions O
made O
- O
for O
correlations O
to O
surveillance O
genotype O
study O
the O
. O
patients O
regimens O
most O
and O
this O
prophylactic O
may O
those O
phenotype O
in O
treatment O
Extended O
CONCLUSIONS O
life O
with O
determine O
appropriate O
associated O
 
FAP B
acid O
associated O
. O
non O
colorectal B
. O
nature O
evidence O
patients O
of O
with O
for O
changes O
provided O
both O
in O
the O
pathological O
also O
amino O
Study O
FAP O
this O
- O
cancer I
and O
APC O
 
the O
. O
and O
polyposis I
risk O
of O
polymorphism O
Inherited B
colorectal I
APC O
I1307K O
cancer B
 
, O
gene O
respectively O
syndrome I
to O
- O
carcinogenesis O
. O
and O
colorectal O
adenomatous I
in O
are O
the O
APC B
germ O
familial B
thought O
Line O
mutations O
initiate O
and O
of O
sporadic O
formation O
truncating O
colorectal B
tumor I
polyposis I
somatic O
 
I1307K O
lysine O
- O
6 O
> O
of O
( O
7 O
polymorphism O
population O
the O
identified O
% O
the O
- O
isoleucine O
codon O
Jewish O
has O
gene O
Ashkenazi O
been O
Recently O
. O
% O
an O
- O
1307 O
of O
at O
APC B
in O
) O
, O
 
polymorphism O
subjects O
for O
have O
APC B
. O
with O
, I
adenomatous B
colorectal B
in O
unselected O
the O
APC O
. O
carcinogenesis O
this O
Jewish O
common O
cohort O
colorectal O
of O
or O
risk O
, O
variant O
cancer I
To O
I1307K O
assess O
we O
large O
of O
analyzed O
the O
a O
and O
allelic O
polyps I
Ashkenazi O
 
I1307K O
476 O
( O
was O
APC O
patients O
) O
. O
identified O
The O
allele O
1 O
10 O
. O
48 O
in O
of O
% O
 
frequency O
, O
is O
. O
with O
control O
an O
relative O
groups O
APC O
1 O
two O
separate O
of O
population O
the O
associated O
risk O
estimated O
Compared O
I1307K O
with O
in O
the O
allele O
 
5 O
1 O
- O
. O
 
= O
for O
7 O
. O
P O
) O
colorectal B
. O
neoplasia I
( O
01 O
both O
 
carriers O
noncarriers O
per O
increased O
( O
at O
. O
and O
well O
= O
as O
, O
a O
numbers O
colorectal B
as O
younger O
of O
adenomas B
APC O
diagnosis O
03 O
P O
had O
with O
. O
) O
, O
I1307K O
Compared O
age O
furthermore O
, O
patient O
cancers I
 
contributes O
colorectal B
formation O
4 O
I1307K O
variant O
we O
% O
Jewish O
directly O
3 O
leads O
adenoma B
that O
and O
. O
Ashkenazi O
Conclude O
to O
the O
% O
APC O
- O
increased O
of O
cancer I
all O
to O
 
- O
prevention O
and O
this O
term O
, O
justify O
The O
of O
may O
specific O
outcome O
risk O
studies O
this O
expected O
360 O
to O
testing O
in O
, O
long O
for O
. O
genetic O
Americans O
cancer I
for O
the O
- O
may O
setting O
on O
carriers O
harbor O
relative O
colorectal B
population O
clinical O
impact O
allele O
in O
screening O
the O
000 O
significantly O
estimated O
 
and O
grade O
loss O
of O
carcinomas I
- I
human O
its O
high O
, O
breast I
- O
Localization O
in O
BRCA1 O
non B
. O
inherited I
 
ovarian I
of O
established O
suppressor O
is O
, O
in O
non B
hereditary B
gene O
any O
BRCA1 O
the O
and I
and O
cancers I
cancer I
breast I
between O
link O
role O
unclear O
the O
is O
, O
tumour B
. O
familial I
- O
, O
if O
Although O
the O
- I
BRCA1 O
 
of O
expression O
- I
BRCA1 O
to O
from O
and I
are O
reduced O
, O
rare O
but O
BRCA1 O
non B
ovarian I
resulting O
in O
in O
is O
be O
loss O
postulated O
cancers I
localization O
mutations O
sporadic B
breast I
familial I
incorrect O
subcellular O
important O
or O
. O
cancers I
 
have O
ranged O
into O
golgi O
of O
to O
nuclear O
due O
, O
received O
, O
. O
general O
proteins O
of O
the O
BRCA1 O
, O
exclusively O
invaginations O
ER O
, O
localization O
the O
, O
nucleus O
cytoplasmic O
nuclear O
to O
to O
, O
controversy O
/ O
Epigenetic O
loss O
the O
acceptance O
to O
conditionally O
reports O
not O
from O
has O
regarding O
subcellular O
however O
which O
 
this O
comprehensively O
anti O
resolve O
attempt O
, O
we O
An O
have O
to O
antibodies O
. O
in O
characterized O
issue O
19 O
- O
BRCA1 O
 
in O
those O
from O
. O
protein O
these O
lines O
Reagents O
detect O
220 O
foci O
cell O
derived O
discrete O
in O
malignancies I
including O
breast B
epithelial O
all O
, O
kD O
a O
nuclear O
- O
localized O
 
specimens O
also O
revealed O
human O
. O
BRCA1 O
staining O
breast O
invasive B
breast O
Immunohistochemical O
of O
- I
cancers I
carcinomas I
in O
benign O
nuclear O
low B
grade I
foci O
ductal I
and O
, O
lobular I
 
was O
BRCA1 O
sporadic B
undetectable O
the O
ductal B
contribute O
significant O
reduced O
to O
pathogenesis O
carcinomas I
. O
. O
grade O
BRCA1 O
, O
of O
, O
high O
of O
suggesting O
absence O
expression O
cancers I
percentage O
, O
in O
of O
the O
breast I
Conversely O
- O
of O
or O
majority O
a O
that O
may O
 
